TrialCirculation. Cardiovascular quality and outcomes2010

Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk".

Paul M Ridker et al.PubMed ↗Publisher ↗

No numbers read from the abstract.